ArticleDiscover oncology2026
Identification of biomarkers associated with diagnosis of gastroesophageal junction adenocarcinoma and their correlation with immune infiltration.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastroesophageal junction adenocarcinoma (GEJAC) is a highly lethal malignancy, and its molecular mechanisms are still not well understood. Reliable biomarkers for early diagnosis and immunotherapy are urgently needed. This study sought to identify hub genes linked to GEJAC by analyzing datasets from the Gene Expression Omnibus (GEO) and examining their correlation with immune cell infiltration.
methodsTranscriptome data of GEJAC samples and matched normal controls were obtained from GEO. Differentially expressed genes were identified, followed by WGCNA to determine hub genes. Functional annotation was carried out through GO, KEGG, and PPI network analysis to elucidate their biological significance. A diagnostic prediction model was established using logistic regression, and its accuracy was validated through ROC curve analysis. Immune cell composition was assessed with the CIBERSORT algorithm, and the associations between hub genes and immune cell subsets were further investigated.
resultsA total of 392 genes with differential expression were identified, among which 47 overlapping candidates were screened by intersecting WGCNA modules with DEGs. Functional enrichment analysis revealed that these genes were involved in meiotic nuclear division, mitotic cell cycle checkpoint, and the p53 signaling pathway. Five hub genes (TPX2, CCNB2, BUB1, TOP2A, ASPM) were selected for the construction of a diagnostic model, which achieved strong predictive performance (AUC = 0.9). Immune infiltration analysis revealed an inverse relationship between all five hub genes and resting memory CD4 + T cells, as well as a positive relationship with activated memory CD4 + T cells.
conclusionThis study identified TPX2, CCNB2, BUB1, TOP2A, and ASPM as potential candidate diagnostic biomarkers for GEJAC at the transcriptomic level. These genes are closely associated with immune cell infiltration, providing new insights into GEJAC pathogenesis and potential targets for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.